Market Closed -
Nyse
21:00:02 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
159.7
USD
|
+0.81%
|
|
+9.73%
|
-19.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
63,038
|
78,657
|
115,457
|
68,303
|
90,615
|
72,974
|
-
|
-
|
Enterprise Value (EV)
1 |
67,551
|
82,252
|
118,564
|
72,626
|
95,138
|
77,306
|
76,764
|
76,318
|
P/E ratio
|
42.6
x
|
48.4
x
|
57.1
x
|
32.6
x
|
38.9
x
|
29.2
x
|
26.4
x
|
24.4
x
|
Yield
|
0.52%
|
0.51%
|
0.44%
|
0.92%
|
0.79%
|
1.06%
|
1.21%
|
1.35%
|
Capitalization / Revenue
|
10.1
x
|
11.8
x
|
14.8
x
|
8.45
x
|
10.6
x
|
7.97
x
|
7.45
x
|
6.99
x
|
EV / Revenue
|
10.8
x
|
12.3
x
|
15.2
x
|
8.99
x
|
11.1
x
|
8.44
x
|
7.84
x
|
7.31
x
|
EV / EBITDA
|
24.6
x
|
28
x
|
34.5
x
|
20.4
x
|
25.6
x
|
19.3
x
|
17.6
x
|
16.5
x
|
EV / FCF
|
50.6
x
|
49.2
x
|
68.3
x
|
54.8
x
|
58.7
x
|
36.2
x
|
31.6
x
|
28.3
x
|
FCF Yield
|
1.98%
|
2.03%
|
1.46%
|
1.83%
|
1.7%
|
2.77%
|
3.17%
|
3.54%
|
Price to Book
|
23.2
x
|
20.9
x
|
25.4
x
|
15.4
x
|
18.1
x
|
12.2
x
|
10.4
x
|
8.57
x
|
Nbr of stocks (in thousands)
|
476,299
|
475,268
|
473,126
|
466,072
|
459,114
|
456,947
|
-
|
-
|
Reference price
2 |
132.4
|
165.5
|
244.0
|
146.6
|
197.4
|
159.7
|
159.7
|
159.7
|
Announcement Date
|
13/02/20
|
16/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,260
|
6,675
|
7,776
|
8,080
|
8,544
|
9,157
|
9,797
|
10,442
|
EBITDA
1 |
2,743
|
2,940
|
3,434
|
3,561
|
3,722
|
4,006
|
4,362
|
4,631
|
EBIT
1 |
2,331
|
2,499
|
2,986
|
3,096
|
3,231
|
3,535
|
3,857
|
4,178
|
Operating Margin
|
37.24%
|
37.44%
|
38.4%
|
38.32%
|
37.82%
|
38.6%
|
39.37%
|
40.01%
|
Earnings before Tax (EBT)
1 |
1,801
|
1,996
|
2,488
|
2,656
|
2,936
|
3,243
|
3,481
|
3,736
|
Net income
1 |
1,500
|
1,638
|
2,037
|
2,114
|
2,344
|
2,540
|
2,763
|
2,987
|
Net margin
|
23.96%
|
24.54%
|
26.2%
|
26.16%
|
27.43%
|
27.74%
|
28.2%
|
28.6%
|
EPS
2 |
3.110
|
3.420
|
4.270
|
4.490
|
5.070
|
5.475
|
6.038
|
6.556
|
Free Cash Flow
1 |
1,335
|
1,673
|
1,736
|
1,326
|
1,621
|
2,138
|
2,432
|
2,699
|
FCF margin
|
21.33%
|
25.06%
|
22.33%
|
16.41%
|
18.97%
|
23.35%
|
24.83%
|
25.85%
|
FCF Conversion (EBITDA)
|
48.67%
|
56.9%
|
50.55%
|
37.24%
|
43.55%
|
53.36%
|
55.76%
|
58.29%
|
FCF Conversion (Net income)
|
89%
|
102.14%
|
85.22%
|
62.72%
|
69.16%
|
84.15%
|
88.05%
|
90.38%
|
Dividend per Share
2 |
0.6920
|
0.8500
|
1.075
|
1.350
|
1.557
|
1.701
|
1.930
|
2.161
|
Announcement Date
|
13/02/20
|
16/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1,990
|
1,967
|
1,986
|
2,052
|
2,002
|
2,040
|
2,000
|
2,180
|
2,151
|
2,213
|
2,148
|
2,324
|
2,309
|
2,364
|
2,274
|
EBITDA
1 |
839
|
756
|
946
|
887
|
879
|
849
|
857
|
-
|
-
|
-
|
898
|
977
|
970
|
962
|
-
|
EBIT
1 |
774
|
639
|
832
|
770
|
764
|
730
|
770
|
877
|
839
|
745
|
829.6
|
925.5
|
914.3
|
864.2
|
891
|
Operating Margin
|
38.89%
|
32.49%
|
41.89%
|
37.52%
|
38.16%
|
35.78%
|
38.5%
|
40.23%
|
39.01%
|
33.66%
|
38.61%
|
39.82%
|
39.6%
|
36.56%
|
39.18%
|
Earnings before Tax (EBT)
1 |
659
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
650
|
768
|
849
|
846
|
840
|
-
|
Net income
1 |
552
|
414
|
595
|
529
|
529
|
461
|
552
|
671
|
596
|
525
|
583.4
|
686.5
|
657.2
|
633.7
|
-
|
Net margin
|
27.74%
|
21.05%
|
29.96%
|
25.78%
|
26.42%
|
22.6%
|
27.6%
|
30.78%
|
27.71%
|
23.72%
|
27.15%
|
29.53%
|
28.46%
|
26.81%
|
-
|
EPS
2 |
1.160
|
0.8700
|
1.260
|
1.120
|
1.130
|
0.9900
|
1.190
|
1.450
|
1.290
|
1.140
|
1.267
|
1.448
|
1.416
|
1.342
|
1.330
|
Dividend per Share
2 |
0.2500
|
0.3250
|
0.3250
|
0.3250
|
0.3250
|
0.3250
|
0.3750
|
0.3750
|
-
|
0.8070
|
0.4150
|
0.4150
|
0.4150
|
0.4150
|
0.4600
|
Announcement Date
|
04/11/21
|
15/02/22
|
05/05/22
|
04/08/22
|
03/11/22
|
14/02/23
|
04/05/23
|
08/08/23
|
02/11/23
|
13/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
4,513
|
3,595
|
3,107
|
4,323
|
4,523
|
4,331
|
3,790
|
3,343
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.645
x
|
1.223
x
|
0.9048
x
|
1.214
x
|
1.215
x
|
1.081
x
|
0.8688
x
|
0.722
x
|
Free Cash Flow
1 |
1,335
|
1,673
|
1,736
|
1,326
|
1,621
|
2,138
|
2,432
|
2,699
|
ROE (net income / shareholders' equity)
|
71.7%
|
56.9%
|
49%
|
47.3%
|
52.3%
|
61.9%
|
45.8%
|
42.5%
|
ROA (Net income/ Total Assets)
|
15.7%
|
14.7%
|
14.8%
|
14.7%
|
16%
|
17%
|
17.1%
|
17.2%
|
Assets
1 |
9,539
|
11,172
|
13,754
|
14,413
|
14,606
|
14,949
|
16,133
|
17,333
|
Book Value Per Share
2 |
5.690
|
7.930
|
9.610
|
9.490
|
10.90
|
13.10
|
15.30
|
18.60
|
Cash Flow per Share
2 |
3.730
|
4.440
|
4.640
|
4.060
|
5.090
|
6.260
|
7.040
|
7.860
|
Capex
1 |
460
|
453
|
477
|
586
|
732
|
858
|
874
|
834
|
Capex / Sales
|
7.35%
|
6.79%
|
6.13%
|
7.25%
|
8.57%
|
9.37%
|
8.93%
|
7.99%
|
Announcement Date
|
13/02/20
|
16/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
Last Close Price
159.7
USD Average target price
213.9
USD Spread / Average Target +33.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.09% | 72.97B | | -8.93% | 6.69B | | +21.38% | 3.6B | | +2.70% | 1.44B | | -16.99% | 1.34B | | -8.79% | 1.25B | | -26.05% | 1.24B | | -12.71% | 1.15B | | -4.03% | 1.01B | | -23.05% | 817M |
Veterinary Drugs
|